Literature DB >> 1374175

Prostate specific antigen in diagnosis, staging, and follow-up of prostate cancer.

E H Cooper1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1374175     DOI： 10.1002/pros.2990210520

Source DB:  PubMed          Journal:  Prostate Suppl        ISSN： 1050-5881


× No keyword cloud information.
  3 in total

1.  Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.

Authors:  William D Figg; Michael E Franks; David Venzon; Paul Duray; Michael C Cox; W Marston Linehan; W Van Bingham; James A Eastham; Eddie Reed; Oliver Sartor
Journal:  World J Urol       Date:  2004-12-08       Impact factor: 4.226

2.  Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer.

Authors:  S Hori; T Jabbar; N Kachroo; J C Vasconcelos; C N Robson; V J Gnanapragasam
Journal:  J Cancer Res Clin Oncol       Date:  2011-02       Impact factor: 4.553

3.  Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer.

Authors:  Atsushi Tomioka; Nobumichi Tanaka; Motokiyo Yoshikawa; Makito Miyake; Satoshi Anai; Yoshitomo Chihara; Eijiro Okajima; Akihide Hirayama; Yoshihiko Hirao; Kiyohide Fujimoto
Journal:  BMC Urol       Date:  2014-04-29       Impact factor: 2.264
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.